Cost-effectiveness data on biologics needed

Article Abstract:

Biotech companies from Europe and United States have started gathering data that would enable them to demonstrate the value of their products, as there is an absence of pharmacoeconomic model for assessing the cost effectiveness of biotech drugs. The main challenge for drug marketers is to generate appropriate data that will enable healthcare providers to understand the value attached to a company's product.

Europe, Science & research, Biological Product (except Diagnostic) Manufacturing, Biological Products, Research, Economic aspects, Pharmaceutical biotechnology

---

Next generation flu vaccine boosted by Chiron debacle

Article Abstract:

Scarcity of vaccines in the United States market could be attributed to the withdrawal of Chiron vaccine from the market. The US is in the process of diversifying their sources of supply, and hence is considering various innovative measures and techniques that will assist in combating the scarcity of vaccines.

Market information - general, Production management, Supply and demand, Influenza vaccines, Biological products industry, Chiron Corp., CHIR

---

Similar abstracts:

• Abstracts: The promise of cancer vaccines. Knocking the SOCS1 off dendritic cells. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras
• Abstracts: The power of "independence": defending and extending the jurisdiction of accounting in the United Kingdom. The withering of tolerance and communication in interdisciplinary accounting studies
• Abstracts: The ironies of vehicle feedback in car design. Effect of button location on driver's visual behavior and safety perception
• Abstracts: Congress passes defense appropriations bill funding weapons. part 2 Congress, administration to seek common ground on export controls
• Abstracts: Health professionals' perspectives in exercise referral: Implications for the referral process. Exercise referral: The public health panacea for physical activity promotion? A critical perspective of exercise referral schemes; their development and evaluation

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.